There are currently 1048 clinical trials in Portland, Oregon looking for participants to engage in research studies. Trials are conducted at various facilities, including Oregon Health & Science University, Oregon Health and Science University /ID# 216891, Providence Portland Medical Center and Providence Saint Vincent Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT05811351
Recruiting
The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
Gender:
All
Ages:
60 years and above
Trial Updated:
06/18/2024
Locations: Casey Eye Institute, Portland, Oregon
Conditions: Geographic Atrophy
Register for Updates
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04586426
Recruiting
The purpose of this study is to identify the recommended Phase 2 regimen(s) (RP2R[s]) and schedule for the study treatment (Part 1), to characterize the safety of the RP2R(s) for the study treatment (Part 2) and to evaluate the anticancer activity of talquetamab + teclistamab in participants with relapsed or refractory multiple myeloma and extramedullary disease (EMD) (Part 3).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Oregon Health And Science University, Portland, Oregon
Conditions: Multiple Myeloma
Register for Updates
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997
Recruiting
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Multiple Myeloma
Register for Updates
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034
Recruiting
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Gender:
All
Ages:
40 years and above
Trial Updated:
06/18/2024
Locations: Oregon Health And Science University, Portland, Oregon
Conditions: Ischemic Stroke; Ischemic Attack, Transient
Register for Updates
Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System
NCT04900298
Recruiting
The investigators hypothesize that the use of a personal hand hygiene system (SafeHavenTM) by anesthesia providers in the adult operating room, combined with a novel infectious pathogen tracking system (OR PathTrac) will decrease participant exposure to pathologic bacteria in the adult operating room.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
06/18/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Surgical Wound Infection, Cross Infection
Register for Updates
Increasing Social Connection Through Crisis Caring Contacts: A Pragmatic Trial
NCT05484297
Recruiting
The main purpose is to learn if sending messages from the VA (called "Caring Contacts") reduces loneliness and improves mental health. The investigators want to understand if these messages are effective in Veterans aged 60 and above who have missed appointments at the VA even though they have health problems. Participants will receive up to 10 postcards mailed in envelopes from a fellow Veteran (Peer Specialist) from their local VA, and will be asked to fill out four surveys. The investigators... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
06/18/2024
Locations: VA Portland Health Care System, Portland, OR, Portland, Oregon
Conditions: Loneliness
Register for Updates
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
NCT04752722
Recruiting
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Oregon Health & Science University (OHSU), Portland, Oregon
Conditions: Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Register for Updates
Depuy Synthes Lower Extremity Shaft Nail Registry
NCT05272631
Recruiting
The purpose of this post-market registry is to monitor the clinical safety and performance (union rates and time to union) of two DePuy Synthes lower extremity shaft nails: RFN-Advanced Retrograde Femoral Nailing System (RFNA) and TN-Advanced Tibial Nailing System (TNA) in participants who have experienced femoral or tibial fractures, respectively, requiring fixation and stabilization or who require a revision due to a malunion or a nonunion.
Gender:
All
Ages:
12 years and above
Trial Updated:
06/17/2024
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Femoral Fractures, Tibial Fractures
Register for Updates
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931
Recruiting
The primary objective of this study is to assess the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the composite endpoint of all-cause mortality (ACM) and total cardiovascular (CV) clinical events.
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
06/17/2024
Locations: Research Site, Portland, Oregon
Conditions: Transthyretin Amyloid Cardiomyopathy
Register for Updates
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/17/2024
Locations: Providence Brain & Spine Institute-research coordinator's office, Portland, Oregon +3 locations
Conditions: Pediatric Migraine
Register for Updates
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
NCT04097145
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitation who have been determined to be at an intermediate or greater estimated risk of mortality with tricuspid valve surgery by the cardiac surgeon with concurrence by the local Heart Team
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
Register for Updates
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
NCT06105021
Recruiting
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A*11:01. The purpose of this study is to find the best dose of AFNT-211 th... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Providence Cancer Institute Franz Clinic, Portland, Oregon
Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Register for Updates